Search results
Results from the WOW.Com Content Network
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
By Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...
The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, [1][2][3] and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the ...
Contents. Ivermectin during the COVID-19 pandemic. Ivermectin is an antiparasitic drug that is well established for use in animals and people. [ 1 ] The World Health Organization (WHO), [ 2 ] the European Medicines Agency (EMA), [ 3 ] the United States Food and Drug Administration (FDA), [ 4 ] and the Infectious Diseases Society of America ...
If approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group Paris and Tarrytown, NY, September 20, 2024. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union ...
In January 2021, the UK National Health Service issued guidance that the immune modulating drugs tocilizumab and sarilumab were beneficial when given promptly to people with COVID-19 admitted to intensive care, following research which found a reduction in the risk of death by 24%.
COVID-19 pandemic. The Solidarity trial for treatments is a multinational Phase III-IV clinical trial organized by the World Health Organization (WHO) and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. [1][2] The trial was announced 18 March 2020, [1] and as of 6 August 2021, 12,000 patients ...
The summer surge of the coronavirus subvariants nicknamed FLiRT has given way to ever more contagious strains, a key reason behind the current high levels of COVID in California and nationwide ...